Effects of Odanacatib on BMD and overall safety in the treatment of Osteoporosis in postmenopausal women previously treated with Alendronate — ASN Events

Effects of Odanacatib on BMD and overall safety in the treatment of Osteoporosis in postmenopausal women previously treated with Alendronate (#52)

Elisabeth Smith 1 , Roland Chapurlat 2 , Tobias De Villiers 3 , Sydney Bonnick 4 , Alberto Odio 5 , Santiago Palacios 6 , Boyd B Scott 1 , Celine Le Bailly De Tilleghem 1 , Carolyn DaSilva 1 , Albert Leung 1 , Deborah Gurner 1
  1. Merck, Sharpe & Dohme Corp., Whitehouse Station, New Jersey, USA
  2. INSERM U1033, Université de Lyon, Hôpital E Herriot, Lyon, France
  3. Dept of Obstetrics and Gynaecology, Mediclinic Panorama, Stellenbosch University, Cape Town, South Africa
  4. Research Center of North Texas , Denton, TEXAS, USA
  5. Alto California Medical Group, Simi Valley, California, USA
  6. Salud y Medicina de la Mujer C/Antonio Acuña, Instituto Palacios, Madrid, Spain
Publish consent withheld
@ESASRB